

CITATION REPORT

List of articles citing

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

DOI: 10.1007/s00280-020-04196-9

Cancer Chemotherapy and Pharmacology, 2021, 87, 349-359.

Source: <https://exaly.com/paper-pdf/77747497/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021 , 35, 337-350	7.9	3
9	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	11
8	Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta [®] in Healthy Chinese Male Volunteers. <i>Frontiers in Pharmacology</i> , 2021 , 12, 660541	5.6	0
7	Biosimilar monoclonal antibodies in China: A patent review. <i>Bioengineered</i> , 2022 , 13, 14503-14518	5.7	
6	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. 2022 , 10, 2045		0
5	Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China. 1-10		
4	Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI. 2022 , 22,		0
3	A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.		0
2	Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study. 1-9		0
1	Biosimilars: navigating the regulatory maze across two worlds. 2023 ,		0